← Back to Search

Anti-inflammatory agent

MYMD-1 600MG for Frailty

Phase 2
Waitlist Available
Led By Lon Lynn, DO
Research Sponsored by MyMD Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28 (8-24 hours post dose)
Awards & highlights

Study Summary

This trial will study if a new drug is effective and safe in treating inflammation in sarcopenia/frailty, which are age-related conditions.

Eligible Conditions
  • Frailty
  • Sarcopenia
  • Aging

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28 (8-24 hours post dose)
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 28 (8-24 hours post dose) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Demonstrate reduction of chronic inflammatory markers in participants treated with MYMD1
Capsule (pharmacologic)
Capsule (pharmacologic)
Secondary outcome measures
Incidence of Treatment-Emergent Adverse Events

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Cohort 3: MYMD1 900mgExperimental Treatment1 Intervention
Subjects randomly assigned to the MYMD1 900mg cohort
Group II: Cohort 2: MYMD1 750mgExperimental Treatment1 Intervention
Subjects randomly assigned to the MYMD1 750 cohort
Group III: Cohort 1: MYMD1 600mgExperimental Treatment1 Intervention
Subjects randomly assigned to the MYMD1 600mg cohort
Group IV: Cohort 4: MYMD1 1050mgActive Control1 Intervention
Subjects randomly assigned to the MYMD1 1050mg cohort
Group V: Cohort 4: Placebo group 1050mgPlacebo Group1 Intervention
Subjects assigned to the 1050mg placebo group
Group VI: Cohort 3: Placebo 900mgPlacebo Group1 Intervention
Subjects assigned to the 900mg placebo group
Group VII: Cohort 2: Placebo 750mgPlacebo Group1 Intervention
Subjects assigned to the 750mg placebo group
Group VIII: Cohort 1: Placebo 600mgPlacebo Group1 Intervention
Subjects assigned to the 600mg placebo group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MYMD-1 900mg
2022
Completed Phase 2
~40
MYMD-1 750mg
2022
Completed Phase 2
~40
MYMD-1 600MG
2022
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

MyMD Pharmaceuticals, Inc.Lead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled
Lon Lynn, DOPrincipal InvestigatorClinical Research of West Florida
Leonard Dunn, MDPrincipal InvestigatorClinical Research of West Florida
3 Previous Clinical Trials
1,743 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does MYMD-1 600MG pose any risks to its users?

"Our team at Power has assessed the safety of MYMD-1 600MG as a 2, due to there being clinical evidence that suggests it is secure but no documents indicating its efficacy."

Answered by AI

Are there any remaining vacancies in this trial that patients can join?

"This ongoing research is on the lookout for qualified participants. The listing to clinicaltrials.gov was first posted on February 1st 2022 and most recently edited March 30th of the same year."

Answered by AI

How many individuals are engaged in this clinical trial?

"Affirmative. Clinicaltrials.gov hosts information that confirms the active recruitment process for this medical experiment, which was originally posted on February 1st 2022 and recently modified on March 30th 2022. This study requires 40 participants to be recruited across 3 distinct sites."

Answered by AI

May I participate in this medical research project?

"Forty elderly individuals diagnosed with sarcopenia aged between 65 and 99 are being admitted to this trial. To be considered, applicants must satisfy the following conditions: a minimum age of 65 years at the time of signing their informed consent form; elevated biomarkers of inflammation (IL-6 ≥2.5 pg/mL or sTNFR1 ≥1500 pg/mL); low gait speed ≤0.8 m/s; Short Physical Performance Battery score ≤ 8 points; weight over 35 kg; adequate dietary intake; able to complete a 4 meter timed walk; assessment and documentation of sarcopenia-related muscle mass loss determined by Dual"

Answered by AI

Are applicants over 30 years of age eligible for participation in this trial?

"The required age range for this trial is 65 to 99, with 35 studies targeting patients younger than 18 and 703 trials focusing on the elderly."

Answered by AI

Who else is applying?

What state do they live in?
Texas
New Jersey
Florida
How old are they?
65+
What site did they apply to?
Clinical Research of West Florida
Johns Hopkins Bayview Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
2022. "Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05283486.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top